A Phase 3 interventional study of Letrozole and Anastrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 263 sites in 20 countries. Open to female participants aged 33 Years to 96 Years. Per ClinicalTrials.gov, last updated 2016-04-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.
Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 6th largest by enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2005, is one of 41 in phase 3, and was the 27th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fujian Cancer Hospital · Sites in China
Ages 18+ · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75 · Women only
Celcuity Inc · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 33 Years to 96 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 83 · Phase 3 45 · Phase 4 17
First in 1998; this study’s year is marked. 11 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,172 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 95 across the 159 interventional studies. Of the 109 that completed or were terminated, 44 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 162 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 3rd largest by enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2005, is one of 45 in phase 3, and was the 21st registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing letrozole in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04486911Shengjing HospitalPyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | 2026-12-01 |
| NCT05286437National Cancer Centre, SingaporePhase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
| NCT02562118National University Hospital, SingaporeNeoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 162 studies testing letrozole in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg by mouth (p.o.) once daily
Drug: Letrozole
1 mg p.o. once daily
Drug: Anastrozole
2.5 mg tablets
1 mg tablets
Disease Free Survival
Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.
Time frame: 84 months
Overall Survival
Overall survival was defined as the time from the date of randomization to the date of death from any cause.
Time frame: 84 months
Time to Development of Distant Metastases
Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.
Time frame: 84 months
Time to Development of Contra Lateral Breast Cancer
Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.
Time frame: 84 months
Distant Disease-free Survival
Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.
Time frame: 84 months
Change From Baseline in Serum Lipid Profiles
Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.
Time frame: baseline, 6, 12, 24, 36, 48 and 60 months
Percentage of Participants Who Experienced Clinical Fracture Events
The incidence of clinical fractures was analyzed.
Time frame: 84 months
Percentage of Participants Who Experienced Cardiovascular Events
The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.
Time frame: 84 months
Participants, who had recently undergone surgery, were randomly assigned in 1:1 ratio to letrozole or anastrozole. Participants received daily treatment until disease recurrence/relapse or for a maximum of 5 years. Participants underwent post-treatment long term follow-up for disease-free survival and overall survival.
| Milestone | Letrozole | Anastrozole |
|---|---|---|
| Started | 2078 | 2094 |
| Intent-to-treat (itt) | 2061 | 2075 |
| Safety set | 2049 | 2062 |
| Completed | 1317 | 1286 |
| Not completed | 761 | 808 |
| Withdrew: Withdrawal by subject | 71 | 79 |
| Withdrew: Protocol violation | 35 | 30 |
| Withdrew: Lost to follow-up | 28 | 35 |
| Withdrew: Disease progression | 196 | 216 |
| Withdrew: Death | 28 | 47 |
| Withdrew: Adverse event | 311 | 296 |
| Withdrew: Administrative problems | 22 | 25 |
| Withdrew: Abnormal test procedure(s) result | 49 | 61 |
| Withdrew: Abnormal laboratory values | 4 | 0 |
| Withdrew: Protocol deviation | 17 | 19 |
Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.
| Months | Letrozole | Anastrozole |
|---|---|---|
| Disease Free Survival | NA (84.14 to NA) | NA (NA to NA) |
Overall survival was defined as the time from the date of randomization to the date of death from any cause.
| Months | Letrozole | Anastrozole |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) |
Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.
| Months | Letrozole | Anastrozole |
|---|---|---|
| Time to Development of Distant Metastases | NA (84.14 to NA) | NA (NA to NA) |
Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.
| Months | Letrozole | Anastrozole |
|---|---|---|
| Time to Development of Contra Lateral Breast Cancer | NA (NA to NA) | NA (NA to NA) |
Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.
| Months | Letrozole | Anastrozole |
|---|---|---|
| Distant Disease-free Survival | NA (84.14 to NA) | NA (NA to NA) |
Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.
| mg/dL | Letrozole | Anastrozole |
|---|---|---|
| 6 months | 5.643 (5.584 to 5.701) | 5.553 (5.495 to 5.611) |
| 12 months | 5.569 (5.510 to 5.629) | 5.511 (5.452 to 5.570) |
| 24 months | 5.508 (5.445 to 5.572) | 5.436 (5.373 to 5.499) |
| 36 months | 5.429 (5.359 to 5.500) | 5.427 (5.357 to 5.497) |
| 48 months | 5.395 (5.323 to 5.468) | 5.366 (5.293 to 5.438) |
| 60 months | 5.375 (5.300 to 5.451) | 5.368 (5.292 to 5.443) |
The incidence of clinical fractures was analyzed.
| Percentage of participants | Letrozole | Anastrozole |
|---|---|---|
| Percentage of Participants Who Experienced Clinical Fracture Events | 9.3 | 8.1 |
The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.
| Percentage of participants | Letrozole | Anastrozole |
|---|---|---|
| Ischemic heart disease | 2.4 | 1.5 |
| Cardiac failures | 1.5 | 0.7 |
| Cerebrovascular accidents | 1.6 | 1.5 |
| Thromboembolic events | 1.2 | 1.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Letrozole | — | 486/2,049 (23.7%) | 1,747/2,049 (85.3%) |
| Anastrozole | — | 520/2,062 (25.2%) | 1,762/2,062 (85.5%) |
| Event | Letrozole | Anastrozole |
|---|---|---|
| PneumoniaInfections and infestations | 16/2049 | 29/2062 |
| Breast reconstructionSurgical and medical procedures | 24/2049 | 16/2062 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 21/2049 | 15/2062 |
| Atrial fibrillationCardiac disorders | 19/2049 | 15/2062 |
| FallInjury, poisoning and procedural complications | 17/2049 | 13/2062 |
| Ankle fractureInjury, poisoning and procedural complications | 14/2049 | 10/2062 |
| SyncopeNervous system disorders | 13/2049 | 4/2062 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 6/2049 | 12/2062 |
| NauseaGastrointestinal disorders | 11/2049 | 6/2062 |
| VomitingGastrointestinal disorders | 11/2049 | 6/2062 |
| Event | Letrozole | Anastrozole |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 983/2049 | 983/2062 |
| Hot flushVascular disorders | 666/2049 | 666/2062 |
| FatigueGeneral disorders | 345/2049 | 341/2062 |
| MyalgiaMusculoskeletal and connective tissue disorders | 232/2049 | 211/2062 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 221/2049 | 224/2062 |
| Back painMusculoskeletal and connective tissue disorders | 207/2049 | 187/2062 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 202/2049 | 172/2062 |
| LymphoedemaVascular disorders | 158/2049 | 177/2062 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 167/2049 | 174/2062 |
| HeadacheNervous system disorders | 127/2049 | 164/2062 |
| Age, Continuous(Years) | Letrozole | Anastrozole | Total |
|---|---|---|---|
| Mean | 63.2 ± 8.48 | 63.1 ± 8.45 | 63.2 ± 8.46 |
| Sex/Gender, Customized(Participants) | Letrozole | Anastrozole | Total |
|---|---|---|---|
| Female | 2061 | 2075 | 4136 |
Showing the first 100 of 263 sites across 20 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2005, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole